Astrazeneca on the Web and Social Media

Astrazeneca News, Fundamentals and Discussion on:

Astrazeneca page on Interactive Investor
Astrazeneca page on Financial Times
Astrazeneca page on ADVFN
Astrazeneca page on London South East
Astrazeneca page on Bloomberg Markets
Astrazeneca page on This is Money
Astrazeneca page on Motley Fool
Astrazeneca page on Proactive Investors

Astrazeneca Socially Speaking

Astrazeneca RNS, News and Media


14 Sep 2017
AstraZeneca PLC - Aspen acquires remaining rights to AZ anaestheticsfrom Interactive Investor
11 Sep 2017
AstraZeneca PLC - Tagrisso potential standard of care in lung cancerfrom Interactive Investor
11 Sep 2017
AstraZeneca PLC - IMFINZI superior PFS in Stage III lung cancerfrom Interactive Investor
7 Sep 2017
AstraZeneca PLC - Celgene and AZ update on Fusion trial programmefrom Interactive Investor
7 Sep 2017
AstraZeneca PLC - AZ tezepelumab cuts exacerbations in severe asthmafrom Interactive Investor
7 Sep 2017
AstraZeneca PLC - AZ Duaklir improves lung function in COPD patientsfrom Interactive Investor
5 Sep 2017
AstraZeneca PLC - Directorate Changefrom Interactive Investor
1 Sep 2017
AstraZeneca PLC - Total Voting Rightsfrom Interactive Investor
29 Aug 2017
AstraZeneca PLC - Faslodex gets US FDA OK for expanded use in breastfrom Interactive Investor
18 Aug 2017
AstraZeneca PLC - Lynparza gets broad FDA approval in ovarian cancerfrom Interactive Investor

Astrazeneca Charted

Astrazeneca Discussion on Interactive Investor

Re: quiet by nick2name

  Thu, 21 Sep 2017 11:34:00 GMT
up another 10+%
By nick2name

Bydureon Trial Results by Proverbs 26 vs 5

  Thu, 14 Sep 2017 21:53:00 GMT
Results from a large-scale Phase 3 clinical trial, EXSCEL, assessing the cardiovascular risk of AstraZeneca's (AZN +0.1%) BYDUREON (exenatide extended-release) in type 2 diabetics showed similarity to placebo. The data were presented at European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon and simultaneously published online in the New England Journal of Medicine.

Patients who received once-weekly BYDUREON did not experience more major adverse cardiac events (MACE) than those receiving placebo (non-inferiority).

The incidence of CV events was actually lower in the treatment arm (11.4% vs. 12.5%) but the difference was not statistically valid (p=0.061). Patients in the exenatide arm had 14% less risk of death from all causes (hazard ratio = 0.86).

BYDUREON is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The company is working with regulatory authorities to include the data in the drug's label.
By Proverbs 26 vs 5

Re: Update on clinical trials by Hawk Eye32

  Mon, 11 Sep 2017 15:46:00 GMT
Neil Woodford, will be pleased and those invested in his funds!!
By Hawk Eye32

Update on clinical trials by Proverbs 26 vs 5

  Mon, 11 Sep 2017 14:24:00 GMT
AstraZeneca– Update on clinical trials – AstraZeneca this morning announced an update on two new treatments, both of which exceeded expectations.
• In the first release, AstraZeneca and MedImmune, its global biologics research and development arm, presented the full progression-free survival (PFS) data from a planned interim analysis of the Phase III PACIFIC trial
• Results show that Imfinzi (durvalumab) demonstrated a statistically-significant and clinically-meaningful improvement in PFS compared to current standard of care with active surveillance in patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy (CRT)
• Results of the Phase III PACIFIC trial show an improvement in PFS of more than 11 months in patients treated with Imfinzi compared to placebo (full details in table below)
• In the second release, the company presented the full results of the Phase III FLAURA trial, which support Tagrisso's (osimertinib) clear potential as a new standard of care (SoC) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)
• Results of the Phase III FLAURA trial demonstrated a superior, clinically-meaningful PFS advantage with Tagrisso compared with current SoC EGFR-TKIs (erlotinib or gefitinib).
By Proverbs 26 vs 5

Positive drug trial reported. by Proverbs 26 vs 5

  Thu, 07 Sep 2017 09:47:00 GMT
AstraZeneca has announced that a study has shown that Duaklir significantly improves lung function in chronic obstructive pulmonary disease patients while a trial showed that tezepelumab cuts exacerbations in severe asthma. AstraZeneca announced positive top-line results from the phase III AMPLIFY trial for Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily), which met its primary endpoints, demonstrating a statistically-significant improvement in lung function in patients with moderate to very severe stable chronic obstructive pulmonary disease (COPD) compared to each individual component (either aclidinium bromide or formoterol). In addition, aclidinium bromide achieved its primary bronchodilation endpoint of demonstrating non-inferiority to tiotropium bromide 18µg once-daily. Dr. Sanjay Sethi, Professor and Chief, Pulmonary, Critical Care and Sleep Medicine at University at Buffalo, The State University of New York, USA and the lead investigator of the trial, said: "These results demonstrate the improvement in lung function achieved by the combination of aclidinium and formoterol compared to single LAMA bronchodilators tiotropium and aclidinium, with comparable safety." AstraZeneca and Amgen Inc announced results from the PATHWAY phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. Tezepelumab is a first-in-class anti-TSLP monoclonal antibody being developed by MedImmune, AstraZeneca's global biologics research and development arm, in collaboration with Amgen. The trial results were published today in the New England Journal of Medicine, and will be followed by an oral presentation on 12 September at the ERS International Congress 2017 in Milan. The PATHWAY trial achieved its primary efficacy endpoint, showing annual asthma exacerbation rate reductions of 61%, 71% and 66% in the tezepelumab arms receiving either 70mg or 210mg every four weeks or 280mg every two weeks, respectively (p<0.001 for all comparisons to placebo). In the trial, tezepelumab was given as an add-on therapy to patients with a history of asthma exacerbations and uncontrolled asthma despite receiving inhaled corticosteroids/long-acting beta-agonists with or without oral corticosteroids and additional asthma controllers. Story provided by
By Proverbs 26 vs 5

Madrid oncology conference by Proverbs 26 vs 5

  Wed, 30 Aug 2017 20:56:00 GMT
Potential share-moving presentations ahead at key European cancer meeting

Aug. 30, 2017 3:38 PM ET|By: Douglas W. House, SA News Editor
The abstract drop for the European Society for Medical Oncology (ESMO) will launch in less than six hours. The conference will take place September 8-12 in Madrid. Presentations to watch:

AstraZeneca (NYSE:AZN): Top-line data from Phase 3 FLAURA study assessing Tagrisso (osimertinib) in EGFR+ NSCLC patients. Primary endpoint: PFS.

Details of Flaura trial in earlier post.
By Proverbs 26 vs 5

by Proverbs 26 vs 5

  Wed, 30 Aug 2017 20:52:00 GMT

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)
By Proverbs 26 vs 5

by Proverbs 26 vs 5

  Wed, 30 Aug 2017 20:52:00 GMT

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)
By Proverbs 26 vs 5

by Proverbs 26 vs 5

  Wed, 30 Aug 2017 20:52:00 GMT

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)
By Proverbs 26 vs 5

Merck /Astrazeneca oncology collaboration by Proverbs 26 vs 5

  Wed, 30 Aug 2017 20:32:00 GMT

What is expected to boost Keytruda sales even more, is the collaboration between Merck and AstraZeneca (AZN). The two companies entered a strategic oncology collaboration to co-develop AstraZeneca’s drug Lynparza for a number of cancer types. Lynparza will be developed as monotherapy and in combination trials with other medicines. The drug will also be developed and commercialized in combination with Merck’s Keytruda and AstraZeneca’s Imfinzi. Merck’s management had this to say about the collaboration:

In addition, we are very much looking forward to collaborating with AstraZeneca in oncology as announced yesterday. We believe LYNPARZA can be a very important product in different indications over time. And the combination of our proven commercial success in oncology launching KEYTRUDA, with AstraZeneca's strong experience, will enable us together to make this product a tremendous success.
The collaboration gives Merck access to more patients, thus enabling Keytruda to generate more revenue
By Proverbs 26 vs 5

FDA approval for Faslodex by Proverbs 26 vs 5

  Tue, 29 Aug 2017 13:11:00 GMT
AstraZeneca's breast cancer drug Faslodex has received approval from the the US Food and Drug Administration. AstraZeneca said the FDA had approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, who have gone through menopause and have not received previous endocrine therapy. It said the FDA approval was based on data from the phase III FALCON trial, which were published in the November 2016 issue of The Lancet. Executive vice-president, head of the oncology business unit, Jamie Freedman, said: "We're pleased that the landmark FALCON trial results demonstrated the efficacy of Faslodex as initial monotherapy treatment for women who are living with HR+ HER2- advanced breast cancer. "This approval, building on more than 15 years of clinical experience, means more patients can have the opportunity to receive Faslodex earlier in the treatment journey." Story provided by
By Proverbs 26 vs 5

Drugmaker news roundup by Proverbs 26 vs 5

  Thu, 24 Aug 2017 08:23:00 GMT
Aug. 24, 2017 4:10 AM ET|By: Yoel Minkoff, SA News Editor
Novartis (NYSE:NVS) has received EU approval for its breast cancer drug Kisqali, boosting its oncology portfolio with a medicine it believes could potentially provide billions of dollars in revenues.

Roche (OTCQX:RHHBY) has been granted a priority review by the FDA for emicizumab, expediting the examination process for its haemophilia drug.

Meanwhile, results from a clinical trial have shown that Astrazeneca's (NYSE:AZN) blood-thinner Brilinta reduces cardiovascular mortality risks by 29% in patients with a history of heart problems.
By Proverbs 26 vs 5

Re: NEW ARTICLE: Stockwatch: Is this a coile... by Proverbs 26 vs 5

  Tue, 22 Aug 2017 08:30:00 GMT
What the author doesn't comment on is that the share price movement for Hikma's generics competitors (TEVA and Mylan) exactly shadows that of Hikma. This movement is directly related to the generics market and not just a function of short selling.
BTW the correct spelling is Boehringer Ingleheim.
By Proverbs 26 vs 5

NEW ARTICLE: Stockwatch: Is this a coiled spring or a falling knife? by II Editor

  Tue, 22 Aug 2017 07:59:00 GMT
"Has a plunge in LSE:HIK:Hikma Pharmaceuticals gone too far, accentuated by short selling? And, hence, is the @GB:MCX:FTSE 250 stock due at least some technical rebound?Or, like a (less savage) drop at @GB:UKX:FTSE 100-listed LSE:SHP:Shire, is it ..."

By II Editor

AstraZeneca Stages Major Lung Cancer Comeback by Proverbs 26 vs 5

  Mon, 21 Aug 2017 08:09:00 GMT
AZ-Merck's Lynparza gets US approval for ovarian cancer and Merck & Co have announced that Lynparza has received additional and broad approval in the US for ovarian cancer. The said the US Food and Drug Administration (FDA) had granted approval for the PARP inhibitor, Lynparza (olaparib), as follows: - New use of Lynparza as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer who are in response to platinum-based chemotherapy, regardless of BRCA status; - New use of Lynparza tablets (2 tablets twice daily) as opposed to capsules (8 capsules twice daily); - Lynparza tablets also now indicated (conversion from the current accelerated approval) for the use in patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. AstraZeneca executive vice-president, global medicines development and chief medical officer, Sean Bohen, said: "Physicians have almost three years of clinical experience with Lynparza on the market and we are now pleased to bring this important medicine, in a new tablet formulation, to a broader group of women. "Today's approvals validate more than 10 years of dedicated research behind Lynparza, the world's first PARP inhibitor, which now provides oncologists with the greater flexibility for use in terms of treatment settings. "It builds on our recently-announced collaboration with Merck, which aims to further increase the number of treatment options available to patients." Story provided by
By Proverbs 26 vs 5